S1+ Paclitaxel (IV & IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
Condition:   Metastatic Gastric Adenocarcinoma Interventions:   Drug: S1;   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Oxaliplatin Sponsor:   China Medical University, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials

One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab
Condition:   Diabetic Macular Edema Intervention:   Drug: Aflibercept Injection [Eylea] Sponsor:   University of Alexandria Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 4, 2019 Category: Research Source Type: clinical trials

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)
Conditions:   Breast Cancer;   Renal Cell Carcinoma Interventions:   Drug: IPI-549;   Drug: Atezolizumab;   Drug: nab-paclitaxel;   Drug: Bevacizumab Sponsors:   Infinity Pharmaceuticals, Inc.;   Roche Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 23, 2019 Category: Research Source Type: clinical trials

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Condition:   Colorectal Cancer Interventions:   Drug: Bevacizumab Injection [Avastin];   Drug: Oxaliplatin;   Drug: Capecitabine;   Biological: PD1-T cells Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 15, 2019 Category: Research Source Type: clinical trials

Multicenter Randomized Controlled Trial on the Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Conditions:   Retinal Telangiectasis;   Coats Disease Interventions:   Drug: Anti-VEGF injections of bevacizumab;   Device: Laser Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 7, 2019 Category: Research Source Type: clinical trials

Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Conditions:   Retinal Telangiectasis;   Coats Disease Interventions:   Drug: Anti-VEGF injections of bevacizumab;   Device: Laser Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 7, 2019 Category: Research Source Type: clinical trials

Multicenter Randomized Controlled Trial on the Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Conditions:   Retinal Telangiectasis;   Coats Disease Interventions:   Drug: Anti-VEGF injections of bevacizumab;   Device: Laser Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 7, 2019 Category: Research Source Type: clinical trials

Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma
Conditions:   Heptocellular Cancer;   Heptocellular Carcinoma;   Metastatic Hepatocellular Carcinoma Interventions:   Drug: durvalumab;   Drug: Doxorubicin-Eluting Beads;   Procedure: TACE;   Drug: bevacizumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2019 Category: Research Source Type: clinical trials